শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে

ইঙ্গিত

Sympres contains moxonidine, a member of the anti-hypertensive drug class used to lower blood pressure. It is prescribed for the treatment of high blood pressure.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Moxonidine has shown relatively potent antihypertensive activity across various animal models. Available experimental evidence indicates that its site of action lies within the central nervous system (CNS). The drug binds to I1 imidazoline receptors and, to a lesser extent, a2-adrenoreceptors. Its therapeutic effect appears to arise from interaction with I1 receptors in the rostral ventrolateral medulla, which reduces sympathetic nerve activity. Unlike other centrally acting antihypertensives, Moxonidine shows only low affinity for central a2-adrenoceptors relative to I1 imidazoline receptors; a2-adrenoceptors are thought to be the molecular target responsible for sedation and dry mouth, the most common side effects seen with this class of drugs. In humans, Moxonidine reduces systemic vascular resistance and, as a result, lowers arterial blood pressure.

Pregnancy & Breastfeeding

Pregnancy Category: B3. Research on the use of moxonidine during pregnancy is limited. Studies in animals have revealed effects on the developing embryo, so moxonidine should be avoided in pregnancy unless the potential benefit is judged to outweigh the possible risk to the baby. Because moxonidine passes into breast-milk, it is not recommended for breastfeeding mothers. If treatment with moxonidine is felt to be necessary, breastfeeding should be discontinued.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Treatment should be started with 200 micrograms in the morning. The dose may be titrated after three weeks to 400 micrograms given as single dose or as divided daily doses (morning and evening) until a satisfactory response is achieved. If the response is still unsatisfactory after a further 3 weeks treatment, the dosage can be increased up to a maximum of 600 micrograms in divided doses (morning and evening). A single dose of 400 micrograms and a daily dose of 600 micrograms of Moxonidine should not be exceeded. Moxonidine may be taken with or without food.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.

প্রধান পারস্পরিক ক্রিয়া

Checker →